Work

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2530

Authors: Rebecca Suk Heist, Leena Gandhi, Geoffrey Shapiro, Naiyer A. Rizvi, Howard A. Burris, Johanna C. Bendell, Jose Baselga, Scott B Yerganian, Karl Hsu, Janet Ogden, Loïc Vincent, Oliver von Richter, Giuseppe Locatelli, Ekatherine Asatiani, Jeffrey R. Infante

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, EMD Serono, Inc. (United States), Sanofi (France), Merck KGaA, Darmstadt (Germany), Merck Serono S.A. (Switzerland)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3012385461

Cites:

Cited by: 28

Related to: 10